AbbVie's RINVOQ (upadacitinib) has been approved in the EU to treat adult patients with active psoriatic arthritis (PsA).
List view / Grid view
Filter the results
Amgen has set out the company's seven-year environmental sustainability plan to achieve carbon neutrality by 2027.
Pfizer-BioNTech COVID-19 vaccine is effective against new, highly transmissible COVID-19 strains, finds study
Research shows that the antibodies induced by the Pfizer-BioNTech COVID-19 vaccine can neutralise SARS-CoV-2 viruses with the N501Y mutation.
Analysts say M&A deals continue to be a core driver of pharma/biopharma industry growth and that 2021 will likely be another year of high deal value.
Unique advantages of incorporating untargeted and targeted metabolomics in drug development and clinical trials
11 December 2020 | By Metabolon
Watch our on-demand webinar as experts discuss the use and benefits of incorporating untargeted and targeted metabolomics into the drug development process.
The European Commission has fined Teva and Cephalon €60.5 million for a pay-for-delay deal over Cephalon's modafinil and Teva's generic.
In this Q&A, Nick Pike, Chief Revenue Officer at Vizibl, outlines with EPR’s Hannah Balfour the benefits of Software as a Service (SaaS) for pharmaceutical companies and describes how its adoption can enable companies to achieve many goals faster; from collaborating on bringing new products to market to reaching their…
Mary Alice Dwyer and Sameer Lal explain how pharmaceutical companies can embrace a more customer-centric approach through digital transformation.
Following approval by Emisphere shareholders, Novo Nordisk will acquire the company for a total of $1.8 billion.
PhRMA has released a statement following the announcement that Joe Biden will be the next President of the US.
GSK will use 100 percent renewable electricity usage among other efforts in its plans to have a net zero impact on the climate by 2030.
A new report has highlighted that despite the pandemic, pharma M&A activity rose but deal value fell in the first half of 2020.